Advertisement

Current Bladder Dysfunction Reports

, Volume 13, Issue 4, pp 191–200 | Cite as

Neurogenic Bladder: Recurrent Urinary Tract Infections—Beyond Antibiotics

  • Alison C. CastleEmail author
  • Albert Park
  • Alissa J. Mitchell
  • Donna Z. Bliss
  • Jeffrey A. Gelfand
  • Elise J. B. De
Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)
  • 81 Downloads
Part of the following topical collections:
  1. Topical Collection on Inflammatory/Infectious Bladder Disorders

Abstract

Purpose of Review

Our goal was to identify evidenced-based strategies to prevent and treat patients with neurogenic bladder who suffer from recurrent urinary tract infections. We focused on therapy beyond standard antibiotics to address a multitude of factors implicated in these complex infections.

Recent Findings

Anatomic and functional components specific to neurogenic bladder contribute to the risk of infection and require close clinical monitoring. The host-pathogen interaction is one that allows for colonization of bacteria in the bladder. We recognize that bacteriuria in the neurogenic bladder population does not equate with infection. Local antibiotic treatment and oral supplements are often not adequate to eliminate infection nor prevent recurrent infection due to biofilms. However, novel medical therapies, such as photodynamic therapy, bacterial interference, and infrared laser therapy to augment local immune cells, are promising options to prevent and treat symptomatic infection.

Summary

A combination approach including management of anatomic and functional factors with medical intervention can significantly improve frequency of urinary infection. Further study of non-antibiotic therapeutic strategies is much needed as we recognize the complexity of the urinary biomes and the limitations of antibiotic therapies.

Keywords

Neurogenic bladder Neurogenic UTI Recurrent urinary tract infection Catheter-associated UTI 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Smelov V, Naber K, Johansen TE. Letter to the editor: diagnostic criteria in urological diseases do not always match with findings by extended culture techniques and metagenomic sequencing of 16S rDNA. Open Microbiol J. 2016;10(1):23–6.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Busscher GJ, Bos R, Van der Mei HC. Initial microbial adhesion is a determinant for strength of biofilm adhesion. FEMS Microbiol Lett. 1995;128:229–34.PubMedGoogle Scholar
  3. 3.
    Goetz LL, Klausner AP. Strategies for prevention of urinary tract infections in neurogenic bladder dysfunction. Phys Med Rehabil Clin N Am. 2014;25(3):605–18.PubMedGoogle Scholar
  4. 4.
    Norden CW, Green GM, Kass EH. Antibacterial mechanisms of the urinary bladder. J Clin Invest. 1968 Dec;47(12):2689–700.PubMedPubMedCentralGoogle Scholar
  5. 5.
    McKibben MJ, Seed P, Ross SS, Borawski KM. Urinary tract infection and neurogenic bladder. Urol Clin North Am. 2015 Nov;42(4):527–36.PubMedGoogle Scholar
  6. 6.
    Bergamin PA, Kiosoglous AJ. Surgical management of recurrent urinary tract infections: a review. Translational Androl Urol. 2017;6(Suppl 2):S153–62.Google Scholar
  7. 7.
    Wilde MH, McMahon JM, McDonald MV, et al. Self-management intervention for long-term indwelling urinary catheter users: randomized clinical trial. Nurs Res. 2015;64(1):24–34.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Kim BR, Lim JH, Lee SA, Kim JH, Koh SE, Lee IS, et al. The relation between postvoid residual and occurrence of urinary tract infection after stroke in rehabilitation unit. Ann Rehabil Med. 2012;36(2):248–53.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Dromerick AW, Edwards DF. Relation of postvoid residual to urinary tract infection during stroke rehabilitation. Arch Phys Med Rehabil. 2003;84(9):1369–72.PubMedGoogle Scholar
  10. 10.
    Krebs J, Wöllner J, Pannek J. Risk factors for symptomatic urinary tract infections in individuals with chronic neurogenic lower urinary tract dysfunction. Spinal Cord. 2016;54(9):682–6.PubMedGoogle Scholar
  11. 11.
    Sorokin I, De EJ. Options for independent bladder management in patients with spinal cord injury and hand function prohibiting intermittent catheterization. Neurourol Urodyn. 2013;34(2):167–76.  https://doi.org/10.1002/nau.22516.CrossRefPubMedGoogle Scholar
  12. 12.
    Zanetti G, Paparella S, Trinchieri A, Prezioso D, Rocco F, Naber KG. Infections and urolithiasis: current clinical evidence in prophylaxis and antibiotic therapy. Arch Ital Urol Androl. 2008;80(1):5–12.PubMedGoogle Scholar
  13. 13.
    Omar M, Abdulwahab-Ahmed A, Chaparala H, Monga M. Does stone removal help patients with recurrent urinary tract infections? J Urol. 2015;194(4):997–1001.PubMedGoogle Scholar
  14. 14.
    Fouts DE, Pieper R, Szpakowski S, Pohl H, Knoblach S, Suh MJ, et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl Med. 2012;10:174.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Levy J, Breton FL, Jousse M, Haddad R, Verollet D, Guinet-Lacoste A, et al. Bacterial ecology and antibiotic resistance in patients with neurogenic overactive bladder treated by botulinum toxin injections. Ann Phys Rehabil Med. 2013;56:e233.Google Scholar
  16. 16.
    Hiyama Y, Takahashi S, Uehara T, Hashimoto J, Nishinaka K, Kitamura H, et al. Emergence of antimicrobial-resistant uropathogens isolated from pediatric patients with cystitis on daily clean intermittent catheterization. J Infect Chemother. 2015;21(10):703–6.PubMedGoogle Scholar
  17. 17.
    Yoon SB, Lee BS, Lee KD, Hwang SI, Lee HJ, Han ZA. Comparison of bacterial strains and antibiotic susceptibilities in urinary isolates of spinal cord injury patients from the community and hospital. Spinal Cord. 2014;52(4):298–301.PubMedGoogle Scholar
  18. 18.
    Hooton T, Bradley S, Cardenas D, Colgan R, Geerlings S, Rice J, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625–63.PubMedGoogle Scholar
  19. 19.
    Trautner BW, Darouiche RO. Role of biofilm in catheter-associated urinary tract infection. Am J Infect Control. 2004;32(3):177–83.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Groen J, Pannek J, Castro Diaz D, Del Popolo G, Gross T, Hamid R, et al. Summary of European Association of Urology (EAU) guidelines on neuro-urology. Eur Urol. 2016;69(2):324–33.PubMedGoogle Scholar
  21. 21.
    Pannek J, Wöllner J. Management of urinary tract infections in patients with neurogenic bladder: challenges and solutions. Res Rep Urol. 2017;9:121–7.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Forster C, Haslam D, Jackson E, Goldstein S. Utility of a routine urinalysis in children who require clean intermittent catheterization. J Pediatr Urol. 2017;13(5):488.  https://doi.org/10.1016/j.jpurol.2017.01.016.
  23. 23.
    Schlager T, Anderson S, Trudell J, Hendley J. Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. J Urol. 1999;161(1):372.Google Scholar
  24. 24.
    Biering-Sørensen F, Ηøiby N, Nordenbo A, Ravnborg M, Bruun B, Rahm V. Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. J Urol. 1994;151(1):105–8.PubMedGoogle Scholar
  25. 25.
    Mohler JL, Cowen DL, Flanigan RC. Suppression and treatment of urinary tract infection in patients with intermittent catheterized neurogenic bladder. J Urol. 1987;138(2):336–40.PubMedGoogle Scholar
  26. 26.
    Akil I, Ozen C, Cengiz B. Do patient with neurogenic bladder treated with clean intermittent catheterization need antibacterial prophylaxis? Turkish J Med Sci. 2016;46(4):1151–4.Google Scholar
  27. 27.
    Niël-Weise BS, van den Broek PJ, da Silva EMK, Silva LA. Urinary catheter policies for long-term bladder drainage. Cochrane Database Syst Rev. 2012;8  https://doi.org/10.1002/14651858.CD004201.pub3.
  28. 28.
    Chan CY, John AL, Abraham SN. Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity. 2013;38(2):349–59.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Christmas T, Rode J. Characteristics of mast cells in normal bladder, bacterial cystitis and interstitial cystitis. BJU Int. 1991;68(5):473–8.Google Scholar
  30. 30.
    Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci. 2004;3(5):436–50.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Tetz GV, Artemenko NK, Tetz VV. Effect of DNase and antibiotics on biofilm characteristics. Antimicrob Agents Chemother. 2009;53(3):1204–9.PubMedGoogle Scholar
  32. 32.
    Russo TA, Stapleton A, Wenderoth S, Hooton TE, Stamm WE. Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. J Infect Dis. 1995;172(2):440–5.PubMedGoogle Scholar
  33. 33.
    Balsara ZR, Ross SS, Dolber PC, Wiener JS, Tang Y, Seed PC. Enhanced susceptibility to urinary tract infection in the spinal cord-injured host with neurogenic bladder. Infect Immun. 2013;81(8):3018–26.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest. 2007;117(2):289–96.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Esclarin DRA, Garcia LE, Herruzo CR. Epidemiology and risk factors for urinary tract infection in patients with spinal cord injury. J Urol. 2000;164(4):1285–9.Google Scholar
  36. 36.
    Afsar SI, Yemisci OU, Cosar SN, Cetin N. Compliance with clean intermittent catheterization in spinal cord injury patients: a long-term follow-up study. Spinal Cord. 2013;51(8):645–9.PubMedGoogle Scholar
  37. 37.
    Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA. Guideline for prevention of catheter-associated urinary tract infections. Infect Control Hosp Epidemiol. 2010;31(4):319–26. Retrieved from http://www.jstor.org/stable/10.1086/651091 PubMedGoogle Scholar
  38. 38.
    Stamm W. Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention. Am J Med. 1991;99:655–715.Google Scholar
  39. 39.
    •• Durant DJ. Nurse-driven protocols and the prevention of catheter-associated urinary tract infections: a systematic review. Am J Infect Control. 2017;45:1331–41. In this systemic review, nurse driven protocols decreased the prevalence of catheter associated UTIs. PubMedGoogle Scholar
  40. 40.
    Galiczewski JM. Interventions for the prevention of catheter associated urinary tract infections intensive care units: an integrative review. Intensive Crit Care Nurs. 2016;32:1–11.PubMedGoogle Scholar
  41. 41.
    Galiczewski JM, Shurpin KM. An intervention to improve the catheter associated urinary tract infection rate in a medical intensive care unit: direct observation of catheter insertion procedure. Intensive Crit Care Nurs. 2017;40:26–34.PubMedGoogle Scholar
  42. 42.
    Rhone C, Breiter Y, Benson L, Petri H, Thompson P, Murphy C. The impact of two-person indwelling urinary catheter insertion in the emergency department using technical and socioadaptive interventions. J Clin Outcomes Manag. 2017;24(10). Retrived from: https://www.mdedge.com/jcomjournal/article/149684/emergency-medicine/impact-two-person-indwellingurinary-catheter/page/0/1
  43. 43.
    American Nurses Association. Streamlined evidence-based RN tool: catheter associated urinary tract infection (CAUTI) prevention. 2014; https://www.nursingworld.org/~4aede8/globalassets/practiceandpolicy/innovation%2D%2Devidence/clinical-practice-material/cauti-prevention-tool/anacautipreventiontool-final-19dec2014.pdf.
  44. 44.
    Moore KN, Fader M, Getliffe K. Long-term bladder management by intermittent catheterisation in adults and children. Cochrane Database Sys Rev. 2007;  https://doi.org/10.1002/14651858.CD006008.pub2.
  45. 45.
    De Ridder DJ, Everaert K, Fernandez LG, et al. Intermittent catheterisation with hydrophilic-coated catheters (SpeediCath) reduces the risk of clinical urinary tract infection in spinal cord injured patients: a prospective randomised parallel comparative trial. Eur Urol. 2005;48:991–5.PubMedGoogle Scholar
  46. 46.
    Vapnek JM, Maynard FM, Kim J. A prospective randomised trial of the LoFric hydrophilic coated catheter versus conventional plastic catheter for clean intermittent catheterisation. J Urol. 2003;169:994–8.PubMedGoogle Scholar
  47. 47.
    Kanaheswari Y, Kavitha R, Rizal AM. Urinary tract infection and bacteriuria in children performing clean intermittent catheterization with reused catheters. Spinal Cord. 2014;53:209–12.Google Scholar
  48. 48.
    Lucas EJ, Baxter C, Mohamed AZ, Li B, Zhang J, et al. Comparison of the microbiological milieu of patients randomized to either hydrophilic or conventional PVC catheters for clean intermittent catheterization. J Pediatr Urol. 2016;12(3):172.PubMedGoogle Scholar
  49. 49.
    Bermingham SL, Hodgkinson S, Wright S, Hayter E, Spinks J, Pellowe C. Intermittent self catheterisation with hydrophilic, gel reservoir, and non-coated catheters: a systematic review and cost effectiveness analysis. BMJ. 2013;346.  https://doi.org/10.1136/bmj.e8639.
  50. 50.
    Prieto JA, Murphy C, Moore KN, Fader MJ. Intermittent catheterisation for long-term bladder management (abridge Cochrane Review). Neurourol Urodyn. 2015;34(7):648–53.PubMedGoogle Scholar
  51. 51.
    Cooper FP, Alexander CE, Sinha S, et al. Policies for replacing long-term indwelling urinary catheters in adults. Cochrane Database Syst Rev. 2016;7:CD011115.PubMedGoogle Scholar
  52. 52.
    Van Nieuwkoop C, Den Exter PL, Elzevier HW, Den Hartigh J, Van Dissel JT. Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation. Int J Antimicrob Agents. 2010;36(6):485–90.PubMedGoogle Scholar
  53. 53.
    National Clinical Guideline Centre (NICE). Infection: prevention and control of healthcare-associated infections in primary and community care: partial update of NICE clinical guideline 2 (UK). 2012; 10 (139). https://www.ncbi.nlm.nih.gov/books/NBK115272/.
  54. 54.
    Cicione A, Cantiello F, Ucciero G, Salonia A, Torella M, de Sio M, et al. Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: results from a multicentre survey. Can Urol Assoc J. 2014;8(9–10):E721–7.  https://doi.org/10.5489/cuaj.1989.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Tenke P, Kovacs B, Jackel M, Nagy E. The role of biofilm infection in urology. World J Urol. 2006;24(1):13–20.PubMedGoogle Scholar
  56. 56.
    Warren JW. Catheter-associated urinary tract infections. Int J Antimicrob Agents. 2001;17(4):299–303.PubMedGoogle Scholar
  57. 57.
    Nickel JC. Catheter-associated urinary tract infection: new perspectives on old problems. Can J Infect Control. 1991;6:38–42.PubMedGoogle Scholar
  58. 58.
    Cottenden A, Bliss DZ, Buckley B, Fader M, Getliffe K, Paterson J, et al. Management using continence products. International Continence Society. 2017;6:1519–642.Google Scholar
  59. 59.
    Ostaszkiewicz J, Paterson J. Nurses' advice regarding sterile or clean urinary drainage bags for individuals with a long-term indwelling urinary catheter. J Wound Ostomy Continence Nurs. 2012;39(1):77–83.PubMedGoogle Scholar
  60. 60.
    Johnson JR, Kuskowski MA, Wilt TJ. Systematic review: antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients. Ann Intern Med. 2006;144(2):166–26.Google Scholar
  61. 61.
    Saint S, Elmore JG, Sullivan SD, Emerson SS, Koepsell TD. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis. Am J Med. 1998;105(3):236–41.PubMedGoogle Scholar
  62. 62.
    Kowalczuk D, Ginalska G, Piersiak T, Miazga-Karska M. Prevention of biofilm formation on urinary catheters: comparison of the sparfloxacin-treated long-term antimicrobial catheters with silver-coated ones. J Biomed Mater Res B Appl Biomater. 2012 Oct;100(7):1874–82.PubMedGoogle Scholar
  63. 63.
    Riley DK, Classen DC, Stevens LE, Burke JP. A large randomized clinical trial of a silver-impregnated urinary catheter: lack of efficacy and staphylococcal superinfection. Am J Med. 1995 Apr;98(4):349–56.PubMedGoogle Scholar
  64. 64.
    Pickard R, Lam T, Maclennan G, Starr K, Kilonzo M, McPherson G, et al. Types of urethral catheter for reducing symptomatic urinary tract infections in hospitalised adults requiring short-term catheterisation: Multicentre randomised controlled trial and economic evaluation of antimicrobial- and antiseptic-impregnated urethral catheters (the CATHETER trial). Health Technol Assess. 2012;16(47):1–197.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Darouiche RO, Smith JA Jr, Hanna H, et al. Efficacy of antimicrobial-impregnated bladder catheters in reducing catheter-associated bacteriuria: a prospective, randomized, multicenter clinical trial. Urology. 1999;54:976–81.PubMedGoogle Scholar
  66. 66.
    Schumm K, Lam TB. Types of urethral catheters for management of short-term voiding problems in hospitalised adults. Cochrane Database Syst Rev. 2008; 2. Art. No.: CD004013.  https://doi.org/10.1002/14651858.CD004013.pub3.
  67. 67.
    Jahn P, Preuss M, Kernig A, Langer G, Seifert-Huehmer A. Types of indwelling urinary catheters for long-term bladder drainage in adults. Cochrane Database Syst Rev. 2007; 3. Art. No.: CD004997.  https://doi.org/10.1002/14651858.CD004997.pub2.
  68. 68.
    • Singha P, Locklin J, Handa H. A review of the recent advances in antimicrobial coatings for urinary catheters. Acta Biomater. 2017;50:20–40.  https://doi.org/10.1016/j.actbio.2016.11.070. Recent review of coated catheters with a synergistic approach. CrossRefPubMedGoogle Scholar
  69. 69.
    Mandakhalikar K, Chua R, Tambyah P. New technologies for prevention of catheter associated urinary tract infection. Curr Treatment Options Infect Dis. 2016;8(1):24–41.Google Scholar
  70. 70.
    Sundén F, Håkansson L, Ljunggren E, Wullt B. Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying. J Urol. 2010;184(1):179–85.PubMedGoogle Scholar
  71. 71.
    Darouiche R, Green B, Donovan W, Chen D, Schwartz M, Merritt J, et al. Multicenter randomized controlled trial of bacterial interference for prevention of urinary tract infection in patients with neurogenic bladder. Urology. 2011;78(2):341–6.PubMedGoogle Scholar
  72. 72.
    Hull R, Rudy D, Donovan W, Svanborg C, Wieser I, Stewart C, et al. Urinary tract infection prophylaxis using Escherichia coli 83972 in spinal cord injured patients. J Urol. 2000;163(3):872–7.PubMedGoogle Scholar
  73. 73.
    Toh SL, Boswell-Ruys CL, Lee BSB, Simpson JM, Clezy KR. Probiotics for preventing urinary tract infection in people with neuropathic bladder. Cochrane Database Syst Rev. 2017; 9. Art. No.: CD010723.  https://doi.org/10.1002/14651858.CD010723.pub2.
  74. 74.
    •• Huang YY, Wintner A, Seed PC, Brauns T, Gelfand JA, Hamblin MR. Antimicrobial photodynamic therapy mediated by methylene blue and potassium iodide to treat urinary tract infection in a female rat model. Sci Rep. 2018;8(1):7257. Novel approach to treating drug resistant CAUTI PubMedPubMedCentralGoogle Scholar
  75. 75.
    • He Y, Huang YY, Xi L, Gelfand JA, Hamblin MR. Tetracyclines function as dual-action light-activated antibiotics. PloS one. 2018;13(5):e0196485. Tetracycline antibiotics, which may be photoactivated, help prevent regrowth of gram positive and gram negative bacteria in culture media. PubMedPubMedCentralGoogle Scholar
  76. 76.
    •• Wang Y, Wu X, Chen J, Amin R, Lu M, Bhayana B, et al. Antimicrobial blue light inactivation of gram-negative pathogens in biofilms: in vitro and in vivo studies. J Infect Dis. 2016;213(9):1380–7. Blue light can inactive gram negative bacilli and act as antimicrobial agent specifically targeting biofilms PubMedPubMedCentralGoogle Scholar
  77. 77.
    McDermott DH, Liu Q, Velez D, Lopez L, Anaya-O’Brien S, Ulrick J, et al. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood. 2014;123(15):2308–16.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Li B, Zeng Y, Reeves PM, Ran C, Liu Q, Qu X, et al. AMD3100 augments the efficacy of mesothelin-targeted, immune-activating VIC-008 in mesothelioma by modulating intratumoral immunosuppression. Cancer Immunol Res. 2018;6(5):539–51.PubMedGoogle Scholar
  79. 79.
    •• Chen X, Kim P, Farinelli B, Doukas A, Yun SH, Gelfand JA, et al. A novel laser vaccine adjuvant increases the motility of antigen presenting cells. PLoS One. 2010;5(10):e13776. Laser illumination boosts humoral and cell-mediated immune responses PubMedPubMedCentralGoogle Scholar
  80. 80.
    Kimizuka Y, Callahan JJ, Huang Z, Morse K, Katagiri W, Shigeta A, et al. Semiconductor diode laser device adjuvanting intradermal vaccine. Vaccine. 2017;35(18):2404–12.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Gelfand JA, Kashiwagi S, Brauns T, Martin B, Kimizuka Y, Botvinick E, Elkins K, Thomas L, Loscascio J, Parry B, Kelly KM, Poznansky MC. A pilot clinical trial of a near infrared laser vaccine adjuvant: safety, tolerability, and cutaneous immune cell trafficking. FASEB J. 2018 (accepted).Google Scholar
  82. 82.
    Kimizuka Y, Locascio J, Shigeta A, Shibata M, Morse K, Reeves P, Suematsu M, Gelfand J, Brauns T, Poznansky M, Tsukada K, Kashiwagi S. Brief exposures of skin to near-infrared light modulates mast cell function and augments the immune response. J of Immunology. 2018 (accepted).Google Scholar
  83. 83.
    Mody L, Juthani-Mehta M. Urinary tract infections in older women: a clinical review. JAMA. 2014;311(8):844–54.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Liska DJ, Kern HJ, Maki KC. Cranberries and urinary tract infections: how can the same evidence lead to conflicting advice? Adv Nutr. 2016;7(3):498–506.PubMedPubMedCentralGoogle Scholar
  85. 85.
    Howell AB, Botto H, Combescure C, Blanc-Potard AB, Gausa L, Matsumoto T, et al. Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study. BMC Infect Dis. 2010 Apr 14;10:94.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Nicolosi D, Tempera G, Genovese C, Furneri PM. Anti-adhesion activity of A2-type proanthocyanidins (a cranberry major component) on uropathogenic E. coli and P. mirabilis strains. Antibiotics. 2014;3(2):143–54.  https://doi.org/10.3390/antibiotics3020143.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012; Issue 10. Art. No.: CD001321.  https://doi.org/10.1002/14651858.CD001321.pub5.
  88. 88.
    Beerepoot M, Geerlings S. Non-antibiotic prophylaxis for urinary tract infections. Young LS, Svanborg C, eds. Pathogens. 2016;5(2):36.Google Scholar
  89. 89.
    Asma B, Vicky L, Stephanie D, Yves D, Amy H, Sylvie D. Standardised high dose versus low dose cranberry proanthocyanidin extracts for the prevention of recurrent urinary tract infection in healthy women [PACCANN]: a double blind randomised controlled trial protocol. BMC Urol. 2018;18(1):29.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015 Dec 23;12:CD008772.Google Scholar
  91. 91.
    Axelrod DR. Ascorbic acid and urinary pH. JAMA. 1985;254(10):1310–1.PubMedGoogle Scholar
  92. 92.
    Ochoa-Brust GJ, Fernández AR, Villanueva-Ruiz GJ, Velasco R, Trujillo-Hernández B, Vásquez C. Daily intake of 100 mg ascorbic acid as urinary tract infection prophylactic agent during pregnancy. Acta Obstet Gynecol Scand. 2007;86(7):783–7.PubMedGoogle Scholar
  93. 93.
    Castelló T, Girona L, Gómez MR, Mena Mur A, García L. The possible value of ascorbic acid as a prophylactic agent for urinary tract infection. Spinal Cord. 1996;34(10):592–3.PubMedGoogle Scholar
  94. 94.
    Hetey SK, Kleinberg ML, Parker WD, Johnson EW. Effect of ascorbic acid on urine pH in patients with injured spinal cords. Am J Hosp Pharm. 1980 Feb;37(2):235–7.PubMedGoogle Scholar
  95. 95.
    Lo TS, Hammer KD, Zegarra M, Cho WC. Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era. Expert Rev Anti-Infect Ther. 2014 May;12(5):549–54.PubMedGoogle Scholar
  96. 96.
    Lee BS, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012 Oct 17;10:CD003265.PubMedGoogle Scholar
  97. 97.
    Altarac S, Papeš D. Use of D-mannose in prophylaxis of recurrent urinary tract infections (UTIs) in women. BJU Int. 2014 Jan;113(1):9–10.PubMedGoogle Scholar
  98. 98.
    Kranjčec B, Papeš D, Altarac S. D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol. 2014 Feb;32(1):79–84.PubMedGoogle Scholar
  99. 99.
    Wagenlehner FM, Ballarini S, Pilatz A, Weidner W, Lehr L, Naber KG. A randomized, double-blind, parallel-group, multicenter clinical study of Escherichia coli-lyophilized lysate for the prophylaxis of recurrent uncomplicated urinary tract infections. Urol Int. 2015;95(2):167–76.PubMedGoogle Scholar
  100. 100.
    Uehling DT, Hopkins WJ, Elkahwaji JE, Schmidt DM, Leverson GE. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections. J Urol. 2003 Sep;170(3):867–9.PubMedGoogle Scholar
  101. 101.
    Habibi M, Asadi Karam MR, Shokrgozar MA, Oloomi M, Jafari A, Bouzari S. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis. Mol Immunol. 2015 Apr;64(2):285–94.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Alison C. Castle
    • 1
    Email author
  • Albert Park
    • 2
    • 3
  • Alissa J. Mitchell
    • 2
  • Donna Z. Bliss
    • 4
  • Jeffrey A. Gelfand
    • 1
    • 5
  • Elise J. B. De
    • 2
    • 6
  1. 1.Department of MedicineMassachusetts General HospitalBostonUSA
  2. 2.Department of UrologyMassachusetts General HospitalBostonUSA
  3. 3.Department of Physical Medicine and RehabilitationSpaulding Rehabilitation HospitalBostonUSA
  4. 4.School of NursingUniversity of MinnesotaMinneapolisUSA
  5. 5.Division of Infectious DiseaseMassachusetts General HospitalBostonUSA
  6. 6.Spaulding Rehabilitation NetworkMassachusetts General HospitalBostonUSA

Personalised recommendations